Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS study group

Alessandro Gringeri, Lorenzo G. Mantovani, Luciana Scalone, Pier Mannuccio Mannucci

Research output: Contribution to journalArticle

Abstract

Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and disability in patients and impairment to the quality of their lives. Recent advances in treatment have brought improvements, but they have done so by absorbing larger amounts of financial resources. This study involved 52 Italian patients with hemophilia with high-responding inhibitors who were longitudinally observed for 18 months to evaluate concomitantly cost of care and quality of life. Overall, 0.6 bleeding episodes per patient per month were recorded. This frequency of events was lower than that reported in other cohorts of patients with hemophilia who were not taking inhibitors. The average monthly cost of care was, in euros, €18 000 (US $18 000) per patient, mainly because of treatment products. Recombinant activated factor VII, mostly used for orthopedic surgery, represented 50% of the expenses. Quality of life, measured through validated questionnaires, was similar to that of patients with severe hemophilia without inhibitors. In particular, physical quality of life was similar to that in patients with diabetes and on dialysis, whereas mental quality of life was comparable to that in the general population. This study shows that hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life.

Original languageEnglish
Pages (from-to)2358-2363
Number of pages6
JournalBlood
Volume102
Issue number7
DOIs
Publication statusPublished - Oct 1 2003

Fingerprint

Hemophilia A
Quality of Life
Costs and Cost Analysis
Factor VIIa
Dialysis
Orthopedics
Medical problems
Surgery
Costs
Rare Diseases
Hemorrhage
Pain
Therapeutics
Population

ASJC Scopus subject areas

  • Hematology

Cite this

Cost of care and quality of life for patients with hemophilia complicated by inhibitors : The COCIS study group. / Gringeri, Alessandro; Mantovani, Lorenzo G.; Scalone, Luciana; Mannucci, Pier Mannuccio.

In: Blood, Vol. 102, No. 7, 01.10.2003, p. 2358-2363.

Research output: Contribution to journalArticle

Gringeri, Alessandro ; Mantovani, Lorenzo G. ; Scalone, Luciana ; Mannucci, Pier Mannuccio. / Cost of care and quality of life for patients with hemophilia complicated by inhibitors : The COCIS study group. In: Blood. 2003 ; Vol. 102, No. 7. pp. 2358-2363.
@article{8bc09e4111934a5fbc1776e0df90debc,
title = "Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIS study group",
abstract = "Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and disability in patients and impairment to the quality of their lives. Recent advances in treatment have brought improvements, but they have done so by absorbing larger amounts of financial resources. This study involved 52 Italian patients with hemophilia with high-responding inhibitors who were longitudinally observed for 18 months to evaluate concomitantly cost of care and quality of life. Overall, 0.6 bleeding episodes per patient per month were recorded. This frequency of events was lower than that reported in other cohorts of patients with hemophilia who were not taking inhibitors. The average monthly cost of care was, in euros, €18 000 (US $18 000) per patient, mainly because of treatment products. Recombinant activated factor VII, mostly used for orthopedic surgery, represented 50{\%} of the expenses. Quality of life, measured through validated questionnaires, was similar to that of patients with severe hemophilia without inhibitors. In particular, physical quality of life was similar to that in patients with diabetes and on dialysis, whereas mental quality of life was comparable to that in the general population. This study shows that hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life.",
author = "Alessandro Gringeri and Mantovani, {Lorenzo G.} and Luciana Scalone and Mannucci, {Pier Mannuccio}",
year = "2003",
month = "10",
day = "1",
doi = "10.1182/blood-2003-03-0941",
language = "English",
volume = "102",
pages = "2358--2363",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Cost of care and quality of life for patients with hemophilia complicated by inhibitors

T2 - The COCIS study group

AU - Gringeri, Alessandro

AU - Mantovani, Lorenzo G.

AU - Scalone, Luciana

AU - Mannucci, Pier Mannuccio

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and disability in patients and impairment to the quality of their lives. Recent advances in treatment have brought improvements, but they have done so by absorbing larger amounts of financial resources. This study involved 52 Italian patients with hemophilia with high-responding inhibitors who were longitudinally observed for 18 months to evaluate concomitantly cost of care and quality of life. Overall, 0.6 bleeding episodes per patient per month were recorded. This frequency of events was lower than that reported in other cohorts of patients with hemophilia who were not taking inhibitors. The average monthly cost of care was, in euros, €18 000 (US $18 000) per patient, mainly because of treatment products. Recombinant activated factor VII, mostly used for orthopedic surgery, represented 50% of the expenses. Quality of life, measured through validated questionnaires, was similar to that of patients with severe hemophilia without inhibitors. In particular, physical quality of life was similar to that in patients with diabetes and on dialysis, whereas mental quality of life was comparable to that in the general population. This study shows that hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life.

AB - Inhibitors in patients with hemophilia are a rare complication of a rare disease causing pain and disability in patients and impairment to the quality of their lives. Recent advances in treatment have brought improvements, but they have done so by absorbing larger amounts of financial resources. This study involved 52 Italian patients with hemophilia with high-responding inhibitors who were longitudinally observed for 18 months to evaluate concomitantly cost of care and quality of life. Overall, 0.6 bleeding episodes per patient per month were recorded. This frequency of events was lower than that reported in other cohorts of patients with hemophilia who were not taking inhibitors. The average monthly cost of care was, in euros, €18 000 (US $18 000) per patient, mainly because of treatment products. Recombinant activated factor VII, mostly used for orthopedic surgery, represented 50% of the expenses. Quality of life, measured through validated questionnaires, was similar to that of patients with severe hemophilia without inhibitors. In particular, physical quality of life was similar to that in patients with diabetes and on dialysis, whereas mental quality of life was comparable to that in the general population. This study shows that hemophilia complicated by inhibitors, a prototype of rare disease, requires high amounts of resources for management that provides a satisfactory quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0141482007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141482007&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-03-0941

DO - 10.1182/blood-2003-03-0941

M3 - Article

C2 - 12816859

AN - SCOPUS:0141482007

VL - 102

SP - 2358

EP - 2363

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -